Deposition of amyloid-β in Alzheimer's disease (AD) activates microglia, which drive cerebral neuroinflammation. This paper showed increased expression of caspase 1 (a component of the NLRP3 (NOD-, LRR- and pyrin domain-containing 3) inflammasome) in brain samples from patients with AD. Mice that lacked Nlrp3 or Casp1 and had mutations associated with familial AD were protected from loss of spatial memory and had enhanced amyloid-β clearance. In another mouse model of AD, Nlrp3 deficiency resulted in decreased deposition of amyloid-β, suggesting that targeting the NLRP3 inflammasome could be beneficial in AD.
ORIGINAL RESEARCH PAPER
Heneka, M. T. et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 19 Dec 2012 (doi:10.1038/nature11729)
Rights and permissions
About this article
Cite this article
Harrison, C. Inflammasome activation in Alzheimer's disease. Nat Rev Drug Discov 12, 102 (2013). https://doi.org/10.1038/nrd3952
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3952